Chicago's Rush University Medical Center has begun to offer a tech-enabled pill that pings patients via their iPads if they forget to take a daily medicine.
The act, which calls for more than $400 million in additional user fees to be collected from the makers of prescription brand drugs, medical devices, generic drugs and biosimilars, looks to expedite new drug approvals. The committee added amendments aimed at increasing competition.
A federal task force this month is issuing recommendations that aim to strengthen cybersecurity across the healthcare industry through the implementation of new security frameworks and an amendment to the Anti-Kickback Statute.
Medical imaging use in the U.S. has dropped significantly after years of widespread growth, leading to curtailed hiring, equipment purchases and reduced access to the technology thanks to cuts in federal reimbursement and new coding arrangements, according to a new study.
Rina Kellogg is among a legion of thousands of women who are speaking up and filing lawsuits against Bayer, for severe medical problems they say were triggered by using Essure.
The company's sales grew year over year despite the February recall of its Lotus heart valve devices.
The proposed law could save manufacturers money by eliminating unnecessary review processes and ultimately reduce the cost of healthcare, the two bill sponsors said.
The federal agency has asked the healthcare and broadband industries how it should promote connected healthcare technologies, which could improve telehealth infrastructure and other innovations.
Franklin Lakes, N.J.-based Becton Dickinson expects the acquisition of C.R. Bard Inc. to boost sales in foreign markets such as China, where it estimates it can earn annual revenue of $1 billion.
CardioNet has agreed to pay HHS $2.5 million for an alleged HIPAA violation, making the company the first wireless health services provider to reach a settlement with HHS.
The Pennsylvania-based company has struggled to attract customers of its wearable drug injectors.
St. Jude Medical, which is now part of Abbott Laboratories, failed to appropriately correct issues found in some of its cardiovascular devices, according to the U.S. Food and Drug Administration.